Hepatitis B Virus Clinical Trial
Official title:
Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease in Clinical Practice.
NCT number | NCT03459521 |
Other study ID # | HMT2 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | September 1, 2017 |
Est. completion date | August 1, 2021 |
Verified date | July 2022 |
Source | Corporacion Parc Tauli |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Cirrhotic patients have an increased risk of infections. In these patients is important to prevent hepatitis B virus (HBV) infection, as it may cause a deterioration of liver function. However, HBV vaccine efficacy in this group of patients is lower than in healthy population. Despite increasing standard doses to double doses or administering an accelerated pattern, the response to HBV vaccination remains suboptimal. For this reason, an alternative strategy may be using vaccines with novel adjuvants such as Fendrix® or the recombinant vaccine HBVAXPRO®. Aim: To assess the adjuvanted HBV vaccine (Fendrix ®) efficacy in patients with chronic liver disease and to understand the kinetics of anti-HBs titers over time in patients who respond to vaccination. Methods: Prospective and multicenter study. Serological markers of HBV will be assessed prospectively in consecutive patients with non-cirrhotic liver disease (permanent abnormal liver blood tests > six months; elastogram ≥8 kilopascal (kPa); serum markers of fibrosis (APRI or FIB-4 ≥ F2); ultrasound changes suggesting chronic liver disease) and cirrhotic patients (diagnosed by liver biopsy and/or non-invasive methods: clinical, blood tests and ultrasound). Seronegative patients will receive four doses of Fendrix ® at 0,1, 2 and 6 months. Antibodies against HBV superficial antigen (anti-HBs) will be determined at 2 months +/- 10 days, six months and one year after having received the fourth dose of the vaccine (to see kinetics). The study will differentiate between responders and non-responders to the vaccine: adequate immunity to HBV will be defined as anti-HBs higher than > 10mUI/mL (standard definition of seroconversion) and> 100mUI/mL. Investigators will evaluate the factors that influence the response, kinetics and safety of the vaccination in patients with chronic liver disease and cirrhosis.
Status | Completed |
Enrollment | 125 |
Est. completion date | August 1, 2021 |
Est. primary completion date | August 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Chronic liver disease patients -non-cirrhotic and cirrhotic- diagnosed by liver biopsy and / or non-invasive methods (by standard clinical, analytical and ultrasound crite-ria) - Negative hepatitis B surface antigen (HBs Ag) and antibody to hepatitis B core antigen (anti-HBc). Exclusion Criteria: - Allergy to vaccine components (sodium chloride, aluminium phosphate) - Active or past HBV infection - Patients previously vaccinated against HBV (regardless of response) - Child-Pugh C - Conditions that cause immunosuppression (HIV infection, chronic renal failure, active neoplasia) - Pregnancy or breastfeeding - Non-immunized HAV infection. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitari Mutua Terrassa | Terrassa | Barcelona/Spain |
Lead Sponsor | Collaborator |
---|---|
Corporacion Parc Tauli |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The durability of anti-HBs titers over time in patients who respond to vaccination. | 1 year | ||
Primary | The proportion of individuals seroconverting with Hepatitis B surface antibody titres of > 10 and > 100 UI/ml. | 8 months | ||
Secondary | Number of Participants With Vaccine-Related Adverse Events as Assessed by CTCAE v4.0 | 8 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02060162 -
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
|
||
Completed |
NCT00912847 -
Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma
|
N/A | |
Completed |
NCT04072211 -
Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District
|
Phase 4 | |
Completed |
NCT01204762 -
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
|
Phase 2 | |
Completed |
NCT00805675 -
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
|
Phase 3 | |
Completed |
NCT02785835 -
Hepatocellular Carcinoma in HIV-infected Patients
|
||
Completed |
NCT03083821 -
A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting
|
Phase 1 | |
Recruiting |
NCT01083251 -
The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection
|
N/A | |
Not yet recruiting |
NCT05752890 -
A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma
|
||
Recruiting |
NCT04231565 -
Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
|
N/A | |
Terminated |
NCT00678587 -
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
|
Phase 3 | |
Completed |
NCT00739752 -
Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics
|
N/A | |
Completed |
NCT03294798 -
Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04385524 -
Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection
|
N/A | |
Enrolling by invitation |
NCT00663182 -
Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis
|
Phase 4 | |
Completed |
NCT00769730 -
Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication
|
N/A | |
Completed |
NCT01438424 -
Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
|
Phase 2 | |
Withdrawn |
NCT04046107 -
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy
|
Phase 1/Phase 2 | |
Completed |
NCT05406089 -
Effects of Antiviral Therapy on Patients With HBV-related HCC
|
||
Completed |
NCT03625258 -
Mutations of the Pre-core Region of Hepatite B Virus (HBV)
|